Cambridge-based health tech startup CardiaTec has secured a £1.4m pre-seed investment to further develop its AI-driven cardiovascular disease treatment.
Founded at the University of Cambridge, CardiaTec is developing a target discovery platform that uses AI to analyse large-scale cardiovascular data. Its platform crunches data across different fields of biology, such as genomics, microbiomics and epigenomics, with the goal of getting a better understanding of how heart disease develops.
“Cardiovascular disease research has been subject to some very positive recent events,” said Raphael Peralta, CEO of CardiaTec.
“We strongly believe, after several decades of stagnated investment and innovation, cardiovascular disease is re-emerging with newfound interest, driven by the application of AI in being able to drive new and meaningful insights to help meet patients’ needs.”
The investment round was led by Laidlaw Scholars Ventures (LSV) and APEX Ventures. The funding for CardiaTec marks the first investment from LSV, which is the recently formed investment arm of the Laidlaw Foundation.
“We are delighted to support this exceptional team on their mission to improve patient outcomes by using AI for good,” said LSV chief investment officer Niall Santamaria.
“Despite the prevalence of cardiovascular ailments, there has been significant under-investment, so we believe these funds will provide CardiaTec with the opportunity to unearth treatments that make a real difference to patients.”
Other participants in the funding round included Crista Galli Ventures, o2h ventures and Cambridge Enterprise.
The post CardiaTec raises £1.4m to tackle heart disease with AI appeared first on UKTN | UK Tech News.